Sarepta疗法 SRPT 深 沪
等待开盘 05-20 09:30:00 美东时间
16.84
-0.170
-1.00%
华盛通- 最 高17.10
- 今 开17.01
- 成交量 120.53万股
- 最 低 16.65
- 昨 收 17.01
- 总市值 17.78亿
- 52周最高 43.9156
- 市盈率 静 --
- 换手率 1.14%
- 52周最低 10.415
- 委 比 36.75%
- 总股本 1.06亿
- 历史最高 181.83
- 量 比 0.47
- 振 幅 2.65%
- 历史最低 0.433
- 每 手 1
- 风险率 5.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immunic Appoints Michael W. Bonney As Board Chairman
Mr. Bonney brings more than three decades of leadership experience in the biopharmaceutical industry, including significant expertise in multiple sclerosis (MS) and broader central nervous system markets. Notably, during
05-19 18:32
Sarepta Therapeutics2026年Q1扭亏为盈 多项研发进展将公布
经济观察网 Sarepta Therapeutics公布2026年第一季度业绩扭亏为盈，同时披露各产品线运营、研发管线推进及监管申报等最新动态。 业绩经营情况...
05-12 23:02
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
Sarepta Therapeutics shares are trading lower. The company reported Q1 financial results.
Sarepta Therapeutics shares are trading lower. The company reported Q1 financia...
05-07 04:56
美股大行评级 | 美国银行、摩根士丹利、JB亨特运输服务、PNC金融服务、Cheniere Energy等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持FibroBiologics"买入"评级，目标价从4美元升至8美元；摩根士丹利：维持Ultragenyx药业"超配"评级，目标价从50美元升至67美元
04-17 11:27
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $5 price target.
04-17 00:59
Sarepta/ Roche Duchenne therapy to face new late-stage trial targeting EU nod
Roche (RHHBY) announced on Thursday that it is initiating a new Phase 3 trial for Elevidys, a treatment it developed with Sarepta Therapeutics (SRPT) for the muscle-wasting disorder. Duchenne muscular...
04-16 22:53
罗氏获欧洲监管机构反馈后，启动Elevidys基因疗法新研究
罗氏公司周四宣布，在收到欧洲药品监管机构的反馈后，将针对其基因疗法 Elevidys 启动一项晚期临床试验。该疗法用于治疗杜氏肌营养不良症（DMD），由罗氏...
04-16 20:44
Notable healthcare headlines for the week: Merck, Medtronic, and Novartis in focus
U.S. stocks ended Friday broadly lower, with selling pressure intensifying across sectors as investors weighed persistent geopolitical risks tied to tensions in the Middle East. The tech-focused Nasda...
03-29 21:05
Nasdaq 100 Enters Correction As 30-Year Yields Near 5%: What's Moving Markets Friday?
U.S. equities tumbled to their lowest levels in nearly seven months on Friday as the Nasdaq 100, heavily weighted toward tech stocks, officially entered correction territory.
03-28 01:09
